# IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Study · id `cardio:ct-nct07473960` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07473960](<https://clinicaltrials.gov/study/NCT07473960>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07473960

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

## Technical summary

Registry record NCT07473960. Randomized; single masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2026-08-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT07473960, source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)
- Started: 2026-04-01 (actual) (ClinicalTrials.gov record NCT07473960, source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2026-08-26 (actual) (ClinicalTrials.gov record NCT07473960, source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)
- Completion: 2026-08-26 (actual) (ClinicalTrials.gov record NCT07473960, source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07473960, source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07473960-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
- Condition: Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
- Intervention (Drug): IBI306
- Intervention (Drug): placebo
- Intervention (Drug): placebo
- Intervention (Drug): IBI306
- Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Innovent Biologics (Suzhou) Co. Ltd. (`cardio:org-innovent-biologics-suzhou-co-ltd`)

## Provenance

Content hash: cbd9d58d857b003b59b48e1de3ee2f4b1a473c01d91a0834860d36de25e2a61f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
